featured
2022 Top Story in Oncology: Nivolumab Plus Chemotherapy for Resectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985.
- Provencio-Pulla M, Nadal E, Gonzalez Larriba JL, et al. Nivolumab + Chemotherapy Versus Chemotherapy as Neoadjuvant Treatment for Resectable Stage IIIA NSCLC: Primary Endpoint Results of Pathological Complete Response (pCR) From Phase II NADIM II Trial. J Clin Oncol. 2022;40(16_suppl):8501.
Disclosure statements are available on the authors' profiles: